Dr. Jordi Monés attend the presentation of the ECLIPSE-I Fovista (E10030) trial

slider-banner_rome_editora_2_50_1

The Investigator Meeting of Ophthotech took place during the 4th Euretina Winter Congress in Rome last weekend. 

At the Meeting,
Dr. Samir Patel, the president and CEO of Ophthotech Corporation, and also advisor to the scientific council of the Barcelona Macula Foundation, presented the ECLIPSE-I Fovista (E10030) trial. Dr. Patel said the trial could herald a new era of combined treatment (anti-PDGF + anti-VEGF) and drew attention to the progress it could mean for treating exudative Age-Related Macular Degeneration (AMD) compared to what is currently on offer.

ECLIPSE-I Fovista (E10030) is a phase III, randomised, double-blind, controlled clinical trial that establishes the efficacy and safety of intravitreous injections of FOVISTA, an inhibitor of platelet-derived growth factor (anti-PDGF). FOVISTA is administered in combination with Lucentis® (anti-VEGF) in order to study its efficacy, together with the present anti-VEGF monotherapy.


Dr. Jordi Monés
, the Medical Director of the Barcelona Macula Foundation,and Dr. Hussein Al Muhtaseb attended the presentation.

Research is the only solution for the future to fight against blindness

It is only with your help that we can fight against blindness

Collaborate